Videos On Demand - ALPIC 2025 (Advanced Learning on Platelets and Thrombosis International Course) | Congress World

ΗΜΕΡΟΜΗΝΙΕΣ

28/11/2025 - 30/11/2025

ΣΥΝΟΛΟ ΕΠΙΣΚΕΨΕΩΝ

509

Videos On Demand

11.00-13.15 | The Most Impactful Studies in Thrombosis and Antithrombotic Therapy in 2024-2025
13.15-14.30 | Research in Progress
15.00-16.00 | Clots and Bugs: Where infection meets Coagulation
16.00-16.30 | Lecture
16.30-18.00 | Thrombotic risk in hematologic and immune diseases. In Collaboration with Hellenic Society of Haematology
18.30-20.00 | Keynote Lectures
20.00-20.30 | Official Opening of ALPIC 2025
20.30-21.00 | Opening Lecture

09.00-10.00 | Complement activation as a trigger of immunothrombosis in specific entities-new insights in diagnosis and treatment
10.00-11.00 | Lifestyle and thrombosis
11.30-12.30 | Management of thrombosis and bleeding in challenging patient populations
12.30-13.00 | Lecture
13.00-14.40 | Clinical Seminar: Uncertainties and challenges in anticoagulation therapy
16.15-17.45 | Interactive EMLTD Workshop. Thrombosis – special aspects in special populations (online session)
17.45-18.15 | Keynote Lecture
18.45-20.15 | Meet the Experts. Metabolic disorders and Atherothrombosis. Pathophysiology, Clinical consequences and Current treatment options
20.15-20.45 | Satellite Lecture

09.15-10.30 | Plenary session: Adjunctive antiplatelet therapy for patients undergoing PCI
10.30-11.00 | Lecture
11.00-12.30 | Clinical Seminar: Diabetes Mellitus
12.30-14.15 | How to Treat Session. Practical Guidance in Stroke Patients
14.15-15.30 | End of ALPIC 2025

28/11/2025

11.00-13.15 | The Most Impactful Studies in Thrombosis and Antithrombotic Therapy in 2024-2025

STOPDAPT-3. Aspirin monotherapy compared with clopidogrel monotherapy was associated with similar cardiovascular and bleeding outcomes beyond 1 month and up to 1 year after percutaneous coronary intervention with drug-eluting stents | S. Daios
9 Προβολές

PRESTIGE-AF. DΟACs versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with AF: A multicentre, open-label, randomised, phase 3 trial | A. Triantafyllou
9 Προβολές

REC-CAGEFREE II. Stepwise DAPT de-escalation in patients after drug coated balloon angioplasty: A multicentre, randomised, open label, assessor blind, non-inferiority trial | S.-F. Papadopoulos
11 Προβολές

POPular PAUSE TAVI. Continuation versus Interruption of Oral Anticoagulation during TAVI. The study favours peri-TAVI OAC discontinuation | M. Didagelos
9 Προβολές

PEERLESS. A Randomized Controlled Trial comparing Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism | T. Zegkos
9 Προβολές

ACE-PROTAVI. Randomized Clinical Trial for Routine Protamine Administration for Bleeding in Transcatheter Aortic Valve Implantation | A. Kouparanis
9 Προβολές

START. Strategies for anticoagulation in patients with thrombocytopenia and cancer-associated thrombosis: design and rationale of the START pilot randomized controlled trial | S. Bountola
9 Προβολές

CREATE. This trial is investigating the discontinuation of antithrombotic therapy after transcatheter aortic valve replacement (TAVR) in patients without a long-term need for anticoagulation or antiplatelet therapy | C. Kakderis
9 Προβολές

DEFIANCE. A randomized controlled trial of mechanical thrombectomy versus anticoagulation alone for iliofemoral deep vein thrombosis. Rationale and design of the study | A. Giannopoulos
8 Προβολές

STOP-CAD. Antithrombotic therapy for stroke prevention in cervical artery dissection. This trial explores antithrombotic strategies for stroke prevention in patients with cervical artery dissection | I. Gravanis-Apostolopoulos
10 Προβολές

FRAIL-AF. A Randomized Controlled Trial which evaluated the Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation | A. Kontana
9 Προβολές

OPTIMAS. A multicentre, blinded-endpoint, phase 4, randomised controlled trial | K. Kaffe
9 Προβολές

PROTECT-HBR. Rationale and design of a randomized trial comparing the efficacy and safety of a potassium-competitive acid blocker versus a proton-pump inhibitor | V. Kyritsi
9 Προβολές

ATTEST-2. A randomised, parallel group, open-label trial which compared tenecteplase versus alteplase for acute stroke within 4·5 h of onset | D. Papadimitriou
11 Προβολές

13.15-14.30 | Research in Progress

North Kynouria Project | A.-M. Louka
14 Προβολές

The effect of punicic acid from pomegranate seed oil on oxidative stress and endothelial dysfunction in type II diabetes | V. Patriarcheas
29 Προβολές

ADAMTs 13 activity and endothelial markers in acute ischemic stroke | E.-M. Makris
15 Προβολές

Key studies shaping the treatment of aggressive Lymphomas | V. Gougoula
9 Προβολές

IPF in acute ischemic stroke | A. Tsankof
13 Προβολές

Differential effect of EPA, DHA and their combination with DOACs on platelet inhibition, in vitro | I. Koutsaliaris
9 Προβολές

15.00-16.00 | Clots and Bugs: Where infection meets Coagulation

Platelets and antiplatelets in sepsis: a glimpse into the future | K. Akinosoglou
12 Προβολές

16.00-16.30 | Lecture

New targets for antithrombotic medications: Seeking to decouple thrombosis from hemostasis | A. Tselepis
8 Προβολές

16.30-18.00 | Thrombotic risk in hematologic and immune diseases. In Collaboration with Hellenic Society of Haematology

Thrombotic anti-PF4 immune disorders | D. Faille
9 Προβολές

Monoclonal Gammopathy of Thrombotic and Bleeding Significance | V. Gkalea
8 Προβολές

18.30-20.00 | Keynote Lectures

Anticoagulants: successes, failures and future promises | J. Douketis
8 Προβολές

Stents and Surgery: The dimension of the problem from different clinical points of view | E. Arnaoutoglou
8 Προβολές

Cancer associated thrombosis: what anticoagulant to choose? | M. Matsagkas
8 Προβολές

20.00-20.30 | Official Opening of ALPIC 2025

Official Opening of ALPIC 2025
7 Προβολές

20.30-21.00 | Opening Lecture

Antithrombotic drugs for ACS in women | J. Morais
7 Προβολές

29/11/2025

09.00-10.00 | Complement activation as a trigger of immunothrombosis in specific entities-new insights in diagnosis and treatment

Antiphospholipid syndrome | E. Lefkou
8 Προβολές

Paroxysmal nocturnal hemoglobinuria | S. Kokori
10 Προβολές

Atypical HUS | E. Gavriilaki
7 Προβολές

10.00-11.00 | Lifestyle and thrombosis

Dietary habits and thrombosis | V. Lambadiari
9 Προβολές

VTE management in obesity | E. Nomikou
9 Προβολές

Addictions and thrombosis | V. Danilatou
10 Προβολές

11.30-12.30 | Management of thrombosis and bleeding in challenging patient populations

Management of VTE in ICU patients | M. Melissopoulou
3 Προβολές

Management of anticoagulation in “end of life” patients | E. Papadakis
8 Προβολές

Bleeding emergencies in Haematological patients | G. Kaiafa
8 Προβολές

12.30-13.00 | Lecture

Platelet -omics in health and disease | E. Kyriakou
8 Προβολές

13.00-14.40 | Clinical Seminar: Uncertainties and challenges in anticoagulation therapy

Direct oral anticoagulants in patients with severe inherited thrombophilia | D. Adamidou
8 Προβολές

Anticoagulation in patients with cirrhosis | A. Protopapas
9 Προβολές

The risk of thrombosis and the choice of antithrombotic therapy in patients with multiple myeloma | E. Katodritou
9 Προβολές

Thromboinflammation in sickle cell disease and its complications | E. Vlachaki
8 Προβολές

When and how to reverse anticoagulants | V. Perifanis
8 Προβολές

16.15-17.45 | Interactive EMLTD Workshop. Thrombosis – special aspects in special populations (online session)

Unique aspects in thrombosis diagnosis and treatment among children and adolescents | C. Male
8 Προβολές

Cerebral sinus vein thrombosis – differences between pediatric and adult patients | S. Levy-Mendelovich
8 Προβολές

17.45-18.15 | Keynote Lecture

Reversal of antiplatelet therapy for major bleeds or emergent procedures | A. Spyropoulos
9 Προβολές

18.45-20.15 | Meet the Experts. Metabolic disorders and Atherothrombosis. Pathophysiology, Clinical consequences and Current treatment options

Obesity, platelet functionality and thrombosis risk. Management options | C. Dimitroula
8 Προβολές

The complex interaction between hypertension, dyslipidemia, platelet functionality and coagulation cascade. Clinical consequences | A. Triantafyllou
9 Προβολές

Effect of major hypolipidemic drugs on thrombosis parameters Implication for cardiovascular risk reduction | D. Agapakis
9 Προβολές

The Anti-Thrombotic Effects of PCSK9 Inhibitors | M. Florentin
10 Προβολές

20.15-20.45 | Satellite Lecture

BTKis and cardiovascular events in CLL: The role of BTKis selectivity and treatment duration | C. Lafaras
9 Προβολές

30/11/2025

09.15-10.30 | Plenary session: Adjunctive antiplatelet therapy for patients undergoing PCI

Management of asymptomatic atrial fibrillation | N. Fragakis
10 Προβολές

Impact of antiplatelet pretreatment on stent thrombosis in patients undergoing PCI in real world practice | K. Kalantzi
8 Προβολές

Aspirin reloading before PCI on chronic aspirin therapy reduces early ischemia without bleeding trade-off | D. Nikas
9 Προβολές

1-Month vs. 12-month DAPT: comparative outcomes after aspirin cessation with supreme healing-targeted stent | I. Zarifis
8 Προβολές

10.30-11.00 | Lecture

Thromboprophylaxis in children with cancer: What’s new | E. Hatzipantelis
8 Προβολές

11.00-12.30 | Clinical Seminar: Diabetes Mellitus

Diabetic Neuropath | T. Didangelos
9 Προβολές

Diabetic Nephropathy | E. Karlafti
9 Προβολές

Antithrombotic therapy in diabetes | E. Ztriva
9 Προβολές

12.30-14.15 | How to Treat Session. Practical Guidance in Stroke Patients

Thrombolysis in acute ischemic stroke | N. Kakaletsis
10 Προβολές

Antiplatelets in ischemic stroke | D. Sagris
8 Προβολές

14.15-15.30 | End of ALPIC 2025

End of ALPIC 2025
7 Προβολές